What mistakes are there in this report about vaccination programme in Delhi?
Answers
Answer:
On Sunday, Indian authorities approved two covid vaccines for emergency use, raising hopes that the scourge can be brought under control once enough people have been granted a shield of immunity by these jabs. Unfortunately, the country’s vaccine approval process has kicked up a controversy. Critics have drawn parallels with China and Russia, which okayed immunization shots they had developed without bothering to place data on their efficacy and safety in the public domain for others to examine. Surely, India cannot be clubbed with nations that frown upon independent scrutiny of an exercise as vital as a vaccination programme. Yet, we have no information on the outcome of final-phase domestic trials that were reported to be underway for the two candidates given a go-ahead: Oxford-AstraZeneca’s vaccine, being made here under the brand Covishield by the Pune-based Serum Institute of India (SII), and Hyderabad-based Bharat Biotech’s Covaxin, which it developed indigenously in alliance with the Indian Council of Medical Research. This awkward opacity has caused some disquiet among experts, especially over the latter, which, unlike Oxford’s jab, does not have global data to support its efficacy claims.